Aurinia initiates rolling submission of a new drug application to the FDA for Voclosporin in the treatment of lupus nephritis

Aurinia Pharmaceuticals has initiated a Rolling Submission of its New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for voclosporin, a next-generation calcineurin inhibitor for the treatment of lupus nephritis (“LN”).